Interon
Interon Laboratories is pioneering a new category of immunotherapy called neuro-immunotherapy, which combines neurobiology and immunology in a novel and non-invasive way. Their technology is based on discoveries made at MIT and Harvard Medical School, and they are developing biologics and small molecule therapeutics to treat neurological and immune disorders.
Industries
Nr. of Employees
small (1-50)
Interon
240 Longwood Ave | Building C Suite 125, Boston, MA 02115
Products
Lead biologic therapeutic program (preclinical)
An early-stage biologic development program targeting neurological and immune disorders.
Lead small-molecule therapeutic program (preclinical)
An early-stage small-molecule development program targeting neurological and immune disorders.
Lead biologic therapeutic program (preclinical)
An early-stage biologic development program targeting neurological and immune disorders.
Lead small-molecule therapeutic program (preclinical)
An early-stage small-molecule development program targeting neurological and immune disorders.
Services
Programs to discover and advance biologic and small-molecule candidates for neurological and immune disorders through early-stage development.
Programs to discover and advance biologic and small-molecule candidates for neurological and immune disorders through early-stage development.
Expertise Areas
- Neuro-immunotherapy
- Neurobiology
- Immunology
- Biologic drug development
Key Technologies
- Neuro-immunomodulation approaches
- Biologic therapeutics
- Small-molecule therapeutics
- Non-invasive therapeutic delivery